The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature

Progress in Retinal and Eye Research

Volumn 29, Issue 4, 2010, Pages 284-311

  Fletcher, Erica L ^a   Phipps, Joanna A ^a   Ward, Michelle M ^a   Vessey, Kirstan A ^a   Wilkinson Berka, Jennifer L ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Amacrince cell; Angiogenesis; Diabetic retinopathy; M ller cell; Retinopathy of prematurity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; BRADYKININ; KALLIKREIN; KININ; PRORENIN; PRORENIN RECEPTOR;

ANGIOGENESIS; BLOOD PRESSURE REGULATION; CELL LOSS; CELL TYPE; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG TARGETING; GABAERGIC SYSTEM; GLAUCOMA; GLIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA AMACRINE CELL; RETINA BLOOD VESSEL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; SUBRETINAL NEOVASCULARIZATION; VASCULARIZATION; VASOCONSTRICTION;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEUROGLIA; NEURONS; RENIN-ANGIOTENSIN SYSTEM; RETINA; RETINAL DISEASES; RETINAL VESSELS;

EID: 77953479027     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2010.03.003     Document Type: Review

References (326)

1. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7(1):41-53.
2. Abdouh M., Khanjari A., Abdelazziz N., Ongali B., Couture R., Hassessian H.M. Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat. Br. J. Pharmacol. 2003, 140(1):33-40.
3. Abramov A.Y., Jacobson J., Wientjes F., Hothersall J., Canevari L., Duchen M.R. Expression and modulation of an NADPH oxidase in mammalian astrocytes. J. Neurosci. 2005, 25(40):9176-9184.
4. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994, 331(22):1480-1487.
5. Aiello L.P., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris F.L., Klein R. Diabetic retinopathy. Diabetes Care 1998, 21(1):143-156.
6. Aizu Y., Oyanagi K., Hu J., Nakagawa H. Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology 2002, 22(3):161-170.
7. Akula J.D., Hansen R.M., Martinez-Perez M.E., Fulton A.B. Rod photoreceptor function predicts blood vessel abnormality in retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2007, 48(9):4351-4359.
8. Alcazar O., Cousins S.W., Striker G.E., Marin-Castano M.E. (Pro)renin receptor is expressed in human retinal pigment epithelium and participates in extracellular matrix remodeling. Exp. Eye Res. 2009.
9. Alcorn D., McCausland J.E., Maric C. Angiotensin receptors and development: the kidney. Clin. Exp. Pharmacol. Physiol. 1996, Suppl. 3:S88-S92.
10. Al-Shabrawey M., Bartoli M., El-Remessy A.B., Platt D.H., Matragoon S., Behzadian M.A., Caldwell R.W., Caldwell R.B. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am. J. Pathol. 2005, 167(2):599-607.
11. Amemiya T. Dark adaptation in diabetics. Ophthalmologica 1977, 174(6):322-326.
12. Ames A., Li Y.Y., Heher E.C., Kimble C.R. Energy metabolism of rabbit retina as related to function: high cost of Na+ transport. J. Neurosci. 1992, 12(3):840-853.
13. Amsterdam A., Nissen R.M., Sun Z., Swindell E.C., Farrington S., Hopkins N. Identification of 315 genes essential for early zebrafish development. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(35):12792-12797.
14. Arden G.B., Wolf J.E., Tsang Y. Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res. 1998, 38(11):1723-1729.
15. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest. 1998, 102(4):783-791.
16. Barnaby A.M., Hansen R.M., Moskowitz A., Fulton A.B. Development of scotopic visual thresholds in retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2007, 48(10):4854-4860.
17. Bearse M.A., Adams A.J., Han Y., Schneck M.E., Ng J., Bronson-Castain K., Barez S. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog. Retin. Eye Res. 2006, 25(5):425-448.
18. Bearse M.A., Han Y., Schneck M.E., Barez S., Jacobsen C., Adams A.J. Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2004, 45(9):3259-3265.
19. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87(1):245-313.
20. Berka J.L., Kelly D.J., Robinson D.B., Alcorn D., Marley P.D., Fernley R.T., Skinner S.L. Adrenaline cells of the rat adrenal cortex and medulla contain renin and prorenin. Mol. Cell. Endocrinol. 1996, 119(2):175-184.
21. Berka J.L., Stubbs A.J., Wang D.Z.-M., Di Nicolantonio R., Alcorn D., Campbell D.J., Skinner S. Renin-containing Muller cells of the retina display endocrine features. Invest. Ophthalmol. Vis. Sci. 1995, 36:1450-1458.
22. Berka J.L., Stubbs A.J., Wang D.Z., DiNicolantonio R., Alcorn D., Campbell D.J., Skinner S.L. Renin-containing Muller cells of the retina display endocrine features. Invest. Ophthalmol. Vis. Sci. 1995, 36(7):1450-1458.
23. Bloomfield S.A., Dacheux R.F. Rod vision: pathways and processing in the mammalian retina. Prog. Retin. Eye Res. 2001, 20(3):351-384.
24. Bresnick G.H., Palta M. Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch. Ophthalmol. 1987, 105(7):929-933.
25. Bresnick G.H., Palta M. Predicting progression to severe proliferative diabetic retinopathy. Arch. Ophthalmol. 1987, 105(6):810-814.
26. Bringmann A., Pannicke T., Grosche J., Francke M., Wiedemann P., Skatchkov S.N., Osborne N.N., Reichenbach A. Muller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 2006, 25(4):397-424.
27. Bui B.V., Armitage J.A., Tolcos M., Cooper M.E., Vingrys A.J. ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 2003, 46(3):401-408.
28. Bui B.V., Rees S.M., Loeliger M., Caddy J., Rehn A.H., Armitage J.A., Vingrys A.J. Altered retinal function and structure after chronic placental insufficiency. Invest. Ophthalmol. Vis. Sci. 2002, 43(3):805-812.
29. Bursell S.E., Clermont A.C., Aiello L.P., Aiello L.M., Schlossman D.K., Feener E.P., Laffel L., King G.L. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999, 22(8):1245-1251.
30. Bursell S.E., Clermont A.C., Shiba T., King G.L. Evaluating retinal circulation using video fluorescein angiography in control and diabetic rats. Curr. Eye Res. 1992, 11(4):287-295.
31. Cao Z., Dean R., Wu L., Casley D., Cooper M.E. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension 1999, 34(3):408-414.
32. Cao Z., Kelly D.J., Cox A., Casley D., Forbes J.M., Martinello P., Dean R., Gilbert R.E., Cooper M.E. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 2000, 58(6):2437-2451.
33. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6(4):389-395.
34. Chan-Ling T., Page M.P., Gardiner T., Baxter L., Rosinova E., Hughes S. Desmin ensheathment ratio as an indicator of vessel stability: evidence in normal development and in retinopathy of prematurity. Am. J. Pathol. 2004, 165(4):1301-1313.
35. Chan-Ling T., Stone J. Degeneration of astrocytes in feline retinopathy of prematurity causes failure of the blood-retinal barrier. Invest. Ophthalmol. Vis. Sci. 1992, 33(7):2148-2159.
36. Chan-Ling T., Tout S., Hollander H., Stone J. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 1992, 33(7):2128-2147.
37. Chaturvedi N., Porta M., Klein R., Orchard T., Fuller J., Parving H.H., Bilous R., Sjolie A.K. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008, 372(9647):1394-1402.
38. Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351(9095):28-31.
39. Chen P., Scicli G.M., Guo M., Fenstermacher J.D., Dahl D., Edwards P.A., Scicli A.G. Role of angiotensin II in retinal leukostasis in the diabetic rat. Exp. Eye Res. 2006, 83(5):1041-1051.
40. Choi H., Leto T.L., Hunyady L., Catt K.J., Bae Y.S., Rhee S.G. Mechanism of angiotensin II-induced superoxide production in cells reconstituted with angiotensin type 1 receptor and the components of NADPH oxidase. J. Biol. Chem. 2008, 283(1):255-267.
41. Chua C.C., Hamdy R.C., Chua B.H. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim. Biophys. Acta 1998, 1401(2):187-194.
42. Chun M.H., Han S.H., Chung J.W., Wässle H. Electron microscopic analysis of the rod pathway of the rat retina. J. Comp. Neurol. 1993, 332(4):421-432.
43. Chung O., Kuhl H., Stoll M., Unger T. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int. 1998, Suppl. 67:S95-S99.
44. Constad W.H., Fiore P., Samson C., Cinotti A.A. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. Am. J. Ophthalmol. 1988, 105(6):674-677.
45. Contrepas A., Walker J., Koulakoff A., Franek K.J., Qadri F., Giaume C., Corvol P., Schwartz C.E., Nguyen G. A role of the (pro)renin receptor in neuronal cell differentiation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 297(2):R250-R257.
46. Cook V.I., Grove K.L., McMenamin K.M., Carter M.R., Harding J.W., Speth R.C. The AT2 angiotensin receptor subtype predominates in the 18 day gestation fetal rat brain. Brain Res. 1991, 560(1-2):334-336.
47. Costagliola C., Verolino M., De Rosa M.L., Iaccarino G., Ciancaglini M., Mastropasqua L. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp. Eye Res. 2000, 71(2):167-171.
48. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Oliveira-dos-Santos A.J., da Costa J., Zhang L., Pei Y., Scholey J., Ferrario C.M., Manoukian A.S., Chappell M.C., Backx P.H., Yagil Y., Penninger J.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417(6891):822-828.
49. Cryotherapy for Retinopathy of Prematurity Group Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch. Ophthalmol. 2001, 119(8):1110-1118.
50. Cullinane A.B., Leung P.S., Ortego J., Coca-Prados M., Harvey B.J. Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. Br. J. Ophthalmol. 2002, 86(6):676-683.
51. Daemen M.J., Lombardi D.M., Bosman F.T., Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 1991, 68(2):450-456.
52. Danser A.H., Derkx F.H., Admiraal P.J., Deinum J., de Jong P.T., Schalekamp M.A. Angiotensin levels in the eye. Invest. Ophthalmol. Vis. Sci. 1994, 35:1008-1018.
53. Danser A.H., van den Dorpel M.A., Deinum J., Derkx F.H., Franken A.A., Peperkamp E., de Jong P.T., Schalekamp M.A. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. 1989, 68(1):160-167.
54. Danser A.H.J., van den Dorpel M.A., Deinum J., Derkx F.H.M., Franken A.A.M., Peperkamp E., de Jong P.T.V.M., Schalekamp M.A.D.H. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinoapthy. J. Clin. Endocrinol. Metab. 1989, 68:160-167.
55. Datum K.H., Zrenner E. Angiotensin-like immunoreactive cells in the chicken retina. Exp. Eye Res. 1991, 53(2):157-165.
56. DCCT The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 1993, 329(14):977-986.
57. Deschepper C.F., Bouhnik J., Ganong W.F. Colocalization of angiotensinogen and glial fibrillary acidic protein in astrocytes in rat brain. Brain Res. 1986, 374(1):195-198.
58. Dhingra A., Jiang M., Wang T.L., Lyubarsky A., Savchenko A., Bar-Yehuda T., Sterling P., Birnbaumer L., Vardi N. Light response of retinal ON bipolar cells requires a specific splice variant of Galpha(o). J. Neurosci. 2002, 22(12):4878-4884.
59. Dijk F., Kamphuis W. An immunocytochemical study on specific amacrine cell subpopulations in the rat retina after ischemia. Brain Res. 2004, 1026(2):205-217.
60. Dong C.J., Hare W.A. GABAc feedback pathway modulates the amplitude and kinetics of ERG b-wave in a mammalian retina in vivo. Vision Res. 2002, 42(9):1081-1087.
61. Dong C.J., Hare W.A. Temporal modulation of scotopic visual signals by A17 amacrine cells in mammalian retina in vivo. J. Neurophysiol. 2003, 89(4):2159-2166.
62. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87(5):E1-E9.
63. Dorrell M.I., Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Prog. Retin. Eye Res. 2006, 25(3):277-295.
64. Downie L.E., Hatzopoulos K.M., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Kalloniatis M., Fletcher E.L. Angiotensin type-1 receptor inhibition is neuroprotective to amacrine cells in a rat model of retinopathy of prematurity. J. Comp. Neurol. 2010, 518(1):41-63.
65. Downie L.E., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Fletcher E.L. Neuronal and glial cell changes are determined by retinal vascularization in retinopathy of prematurity. J. Comp. Neurol. 2007, 504(4):404-417.
66. Downie L.E., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Fletcher E.L. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy. Glia 2008, 56(10):1076-1090.
67. Downie L.E., Vessey K., Miller A., Ward M.M., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Fletcher E.L. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 2009, 161(1):195-213.
68. Downing G.J., Poisner A.M., Barnea E.R. First-trimester villous placenta has high prorenin and active renin concentrations. Am. J. Obstet. Gynecol. 1995, 172(3):864-867.
69. Duarte C.B., Ferreira I.L., Santos P.F., Carvalho A.L., Agostinho P.M., Carvalho A.P. Glutamate in life and death of retinal amacrine cells. Gen. Pharmacol. 1998, 30(3):289-295.
70. Ebrahimian T.G., Tamarat R., Clergue M., Duriez M., Levy B.I., Silvestre J.S. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb. Vasc. Biol. 2005, 25(1):65-70.
71. Essex R.W., Carden S.M., Elder J.E. Two-year results of laser treatment for retinopathy of prematurity at a single neonatal intensive care unit. Clin. Exp. Ophthalmol. 2005, 33(4):390-394.
72. Estacio R.O., Jeffers B.W., Gifford N., Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl. 2):B54-B64.
73. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 1998, 338(10):645-652.
74. Euler T., Schneider H., Wässle H. Glutamate responses of bipolar cells in a slice preparation of the rat retina. J. Neurosci. 1996, 16(9):2934-2944.
75. Euler T., Wässle H. Immunocytochemical identification of cone bipolar cells in the rat retina. J. Comp. Neurol. 1995, 361(3):461-478.
76. Famiglietti E.V., Kolb H. Structural basis for ON-and OFF-center responses in retinal ganglion cells. Science (New York, NY) 1976, 194(4261):193-195.
77. Feke G.T., Buzney S.M., Ogasawara H., Fujio N., Goger D.G., Spack N.P., Gabbay K.H. Retinal circulatory abnormalities in type 1 diabetes. Invest. Ophthalmol. Vis. Sci. 1994, 35(7):2968-2975.
78. Ferrari-Dileo G., Davis E.B., Anderson D.R. Angiotensin binding sites in bovine and human retinal blood vessels. Invest. Ophthalmol. Vis. Sci. 1987, 28(11):1747-1751.
79. Ferrari-Dileo G., Ryan J.W., Rockwood E.J., Davis E.B., Anderson D.R. Angiotensin-converting enzyme in bovine, feline, and human ocular tissues. Invest. Ophthalmol. Vis. Sci. 1988, 29(6):876-881.
80. Filosa J.A., Bonev A.D., Nelson M.T. Calcium dynamics in cortical astrocytes and arterioles during neurovascular coupling. Circ. Res. 2004, 95(10):e73-e81.
81. Fletcher E.L., Kalloniatis M. Neurochemical architecture of the normal and degenerating rat retina. J. Comp. Neurol. 1996, 376(3):343-360.
82. Fletcher E.L., Kalloniatis M. Localisation of amino acid neurotransmitters during postnatal development of the rat retina. J. Comp. Neurol. 1997, 380(4):449-471.
83. Fletcher E.L., Koulen P., Wässle H. GABAA and GABAC receptors on mammalian rod bipolar cells. J. Comp. Neurol. 1998, 396(3):351-365.
84. Fletcher E.L., Phipps J.A., Ward M.M., Puthussery T., Wilkinson-Berka J.L. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr. Pharm. Des. 2007, 13(26):2699-2712.
85. Fletcher E.L., Wässle H. Indoleamine-accumulating amacrine cells are presynaptic to rod bipolar cells through GABA(C) receptors. J. Comp. Neurol. 1999, 413(1):155-167.
86. Fogarty D.J., Matute C. Angiotensin receptor-like immunoreactivity in adult brain white matter astrocytes and oligodendrocytes. Glia 2001, 35(2):131-146.
87. Fogarty D.J., Sanchez-Gomez M.V., Matute C. Multiple angiotensin receptor subtypes in normal and tumor astrocytes in vitro. Glia 2002, 39(3):304-313.
88. Ford C.M., Li S., Pickering J.G. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb. Vasc. Biol. 1999, 19(8):1843-1851.
89. Fortune B., Schneck M.E., Adams A.J. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 1999, 40(11):2638-2651.
90. Frank R.N. Diabetic retinopathy. N. Engl. J. Med. 2004, 350(1):48-58.
91. Franken A.A., Derkx F.H., Schalekamp M.A., Man in t'Veld A.J., Hop W.C., van Rens E.H., de Jong P.T. Association of high plasma prorenin with diabetic retinopathy. J. Hypertens. 1988, Suppl. 6:S461-S463.
92. Fulton A.B., Hansen R.M. Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. J. Opt. Soc. Am. 1996, 13(3):566-571.
93. Fulton A.B., Hansen R.M., Moskowitz A., Akula J.D. The neurovascular retina in retinopathy of prematurity. Prog. Retin. Eye Res. 2009, 28(6):452-482.
94. Fulton A.B., Hansen R.M., Petersen R.A., Vanderveen D.K. The rod photoreceptors in retinopathy of prematurity: an electroretinographic study. Arch. Ophthalmol. 2001, 119(4):499-505.
95. Funatsu H., Yamashita H., Ikeda T., Mimura T., Shimizu E., Hori S. Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am. J. Ophthalmol. 2003, 135(3):321-327.
96. Funck R.C., Wilke A., Rupp H., Brilla C.G. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv. Exp. Med. Biol. 1997, 432:35-44.
97. Gao B.B., Clermont A., Rook S., Fonda S.J., Srinivasan V.J., Wojtkowski M., Fujimoto J.G., Avery R.L., Arrigg P.G., Bursell S.E., Aiello L.P., Feener E.P. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 2007, 13(2):181-188.
98. Gariano R.F. Cellular mechanisms in retinal vascular development. Prog. Retin. Eye Res. 2003, 22(3):295-306.
99. Gariano R.F., Gardner T.W. Retinal angiogenesis in development and disease. Nature 2005, 438(7070):960-966.
100. Gariano R.F., Sage E.H., Kaplan H.J., Hendrickson A.E. Development of astrocytes and their relation to blood vessels in fetal monkey retina. Invest. Ophthalmol. Vis. Sci. 1996, 37(12):2367-2375.
101. Garrido A.M., Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 2009, 302(2):148-158.
102. Gastinger M.J., Singh R.S., Barber A.J. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest. Ophthalmol. Vis. Sci. 2006, 47(7):3143-3150.
103. Gerhardinger C., Costa M.B., Coulombe M.C., Toth I., Hoehn T., Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest. Ophthalmol. Vis. Sci. 2005, 46(1):349-357.
104. Gilbert R.E., Kelly D.J., Cox A.J., Wilkinson-Berka J.L., Rumble J.R., Osicka T., Panagiotopoulos S., Lee V., Hendrich E.C., Jerums G., Cooper M.E. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000, 43(11):1360-1367.
105. Gonzalez B.J., Basille M., Vaudry D., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience 1997, 78(2):419-430.
106. Gordon G.R., Mulligan S.J., MacVicar B.A. Astrocyte control of the cerebrovasculature. Glia 2007, 55(12):1214-1221.
107. Grady E.F., Sechi L.A., Griffin C.A., Schambelan M., Kalinyak J.E. Expression of AT2 receptors in the developing rat fetus. J. Clin. Invest. 1991, 88(3):921-933.
108. Greenstein V.C., Thomas S.R., Blaustein H., Koenig K., Carr R.E. Effects of early diabetic retinopathy on rod system sensitivity. Optom. Vis. Sci. 1993, 70(1):18-23.
109. Greferath U., Grünert U., Wässle H. Rod bipolar cells in the mammalian retina show protein kinase C-like immunoreactivity. J. Comp. Neurol. 1990, 301(3):433-442.
110. Griffin S.A., Brown W.C., MacPherson F., McGrath J.C., Wilson V.G., Korsgaard N., Mulvany M.J., Lever A.F. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991, 17(5):626-635.
111. Guenther E., Hewig B., Zrenner E., Kohler K. Angiotensin II-induced inhibition and facilitation of calcium current subtypes in rat retinal ganglion cells. Neurosci. Lett. 1997, 231(2):71-74.
112. Guenther E., Schmid S., Hewig B., Kohler K. Two-fold effect of Angiotensin II on voltage-dependent calcium currents in rat retinal ganglion cells. Brain Res. 1996, 718(1-2):112-116.
113. Guy J.L., Jackson R.M., Jensen H.A., Hooper N.M., Turner A.J. Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. FEBS J. 2005, 272(14):3512-3520.
114. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., Goronzy J., Weyand C., Harrison D.G. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007, 204(10):2449-2460.
115. Hancock H.A., Kraft T.W. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest. Ophthalmol. Vis. Sci. 2004, 45(3):1002-1008.
116. Hansen R.M., Fulton A.B. Background adaptation in children with a history of mild retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2000, 41(1):320-324.
117. Hard A.L., Wennerholm U.B., Niklasson A., Hellstrom A. Severe ROP in twins after blockage of the renin-angiotensin system during gestation. Acta Paediatr. 2008, 97(8):1142-1144.
118. Hashizume K., Mashima Y., Fumayama T., Ohtake Y., Kimura I., Yoshida K., Ishikawa K., Yasuda N., Fujimaki T., Asaoka R., Koga T., Kanamoto T., Fukuchi T., Miyaki K. Genetic polymorphisms in the angiotensin II receptor gene and their association with open-angle glaucoma in a Japanese population. Invest. Ophthalmol. Vis. Sci. 2005, 46(6):1993-2001.
119. Haydon P.G., Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 2006, 86(3):1009-1031.
120. Heffelfinger S.C. The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des. 2007, 13(12):1215-1229.
121. Henson D.B., North R.V. Dark adaptation in diabetes mellitus. Br. J. Ophthalmol. 1979, 63(8):539-541.
122. Hikichi T., Mori F., Takamiya A., Sasaki M., Horikawa Y., Takeda M., Yoshida A. Inhibitory effect of losartan on laser-induced choroidal neovascularization in rats. Am. J. Ophthalmol. 2001, 132(4):587-589.
123. Hinton A., Bond S., Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch. 2009, 457(3):589-598.
124. Hirooka K., Baba T., Fujimura T., Shiraga F. Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. Am. J. Ophthalmol. 2006, 142(3):523-525.
125. Hirschi K.K., D'Amore P.A. Pericytes in the microvasculature. Cardiovasc. Res. 1996, 32(4):687-698.
126. Hirschi K.K., D'Amore P.A. Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS 1997, 79:419-428.
127. Holopigian K., Greenstein V.C., Seiple W., Hood D.C., Carr R.E. Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 1997, 38(11):2355-2365.
128. Hood D.C., Birch D.G. A quantitative measure of the electrical activity of human rod photoreceptors using electroretinography. Vis. Neurosci. 1990, 5(4):379-387.
129. Horio N., Clermont A.C., Abiko A., Abiko T., Shoelson B.D., Bursell S.E., Feener E.P. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia 2004, 47(1):113-123.
130. Horsburgh G.M., Sefton A.J. Cellular degeneration and synaptogenesis in the developing retina of the rat. J. Comp. Neurol. 1987, 263(4):553-566.
131. Ichihara A., Kaneshiro Y., Suzuki F. Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension. Expert Opin. Investig. Drugs 2006, 15(10):1137-1139.
132. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M., Suzuki F., Nakagawa T., Nishiyama A., Inagami T., Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006, 47(5):894-900.
133. Ichihara A., Suzuki F., Nakagawa T., Kaneshiro Y., Takemitsu T., Sakoda M., Nabi A.H., Nishiyama A., Sugaya T., Hayashi M., Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 2006, 17(7):1950-1961.
134. Ihara Y., Egashira K., Nakano K., Ohtani K., Kubo M., Koga J., Iwai M., Horiuchi M., Gang Z., Yamagishi S., Sunagawa K. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J. Mol. Cell. Cardiol. 2007, 43(4):455-464.
135. Inoue T., Yokoyoma T., Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. Curr. Eye Res. 2001, 23(2):139-143.
136. Inoue T., Yokoyoma T., Mori Y., Sasaki Y., Hosokawa T., Yanagisawa H., Koike H. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits. Curr. Eye Res. 2001, 23(2):133-138.
137. Jacobi P.C., Osswald H., Jurklies B., Zrenner E. Neuromodulatory effects of the renin-angiotensin system on the cat electroretinogram. Invest. Ophthalmol. Vis. Sci. 1994, 35:973-980.
138. Jaiswal N., Diz D.I., Chappell M.C., Khosla M.C., Ferrario C.M. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension 1992, 19(Suppl. 2):II49-II55.
139. Jenkinson K.M., Southwell B.R., Furness J.B. Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor: evidence from quantitation of receptor endocytosis. Br. J. Pharmacol. 1999, 126(1):131-136.
140. Johnson M.A., Lutty G.A., McLeod D.S., Otsuji T., Flower R.W., Sandagar G., Alexander T., Steidl S.M., Hansen B.C. Ocular structure and function in an aged monkey with spontaneous diabetes mellitus. Exp. Eye Res. 2005, 80(1):37-42.
141. Kakinuma Y., Hama H., Sugiyama F., Yagami K., Goto K., Murakami K., Fukamizu A. Impaired blood-brain barrier function in angiotensinogen-deficient mice. Nat. Med. 1998, 4(9):1078-1080.
142. Kakoki M., Kizer C.M., Yi X., Takahashi N., Kim H.S., Bagnell C.R., Edgell C.J., Maeda N., Jennette J.C., Smithies O. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J. Clin. Invest. 2006, 116(5):1302-1309.
143. Kakoki M., Smithies O. The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int. 2009, 75(10):1019-1030.
144. Kakoki M., Takahashi N., Jennette J.C., Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(36):13302-13305.
145. Kalloniatis M., Fletcher E.L. Immunocytochemical localization of the amino acid neurotransmitters in the chicken retina. J. Comp. Neurol. 1993, 336(2):174-193.
146. Kalloniatis M., Marc R.E., Murry R.F. Amino acid signatures in the primate retina. J. Neurosci. 1996, 16(21):6807-6829.
147. Kato H., Suzuki H., Tajima S., Ogata Y., Tominaga T., Sato A., Saruta T. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J. Hypertens. 1991, 9(1):17-22.
148. Kawagishi T., Nishizawa Y., Emoto M., Konishi T., Maekawa K., Hagiwara S., Okuno Y., Inada H., Isshiki G., Morii H. Impaired retinal artery blood flow in IDDM patients before clinical manifestations of diabetic retinopathy. Diabetes Care 1995, 18(12):1544-1549.
149. Kawamura H., Kobayashi M., Li Q., Yamanishi S., Katsumura K., Minami M., Wu D.M., Puro D.G. Effects of angiotensin II on the pericyte-containing microvasculature of the rat retina. J. Physiol. 2004, 561(Pt 3):671-683.
150. Kawamura H., Sugiyama T., Wu D.M., Kobayashi M., Yamanishi S., Katsumura K., Puro D.G. ATP: a vasoactive signal in the pericyte-containing microvasculature of the rat retina. J. Physiol. 2003, 551(Pt 3):787-799.
151. Kelly D.J., Skinner S.L., Gilbert R.E., Cox A.J., Cooper M.E., Wilkinson-Berka J.L. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int. 2000, 57(5):1882-1894.
152. Kelly D.J., Stein-Oakley A., Zhang Y., Wassef L., Maguire J., Koji T., Thomson N., Wilkinson-Berka J.L., Gilbert R.E. Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade. Nephrology (Carlton) 2004, 9(1):7-13.
153. Kelly D.J., Wilkinson-Berka J.L., Allen T.A., Cooper M.E., Skinner S.L. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat. Kidney Int. 1998, 54:343-352.
154. Khakoo A.Y., Sidman R.L., Pasqualini R., Arap W. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?. Cancer Res. 2008, 68(22):9112-9115.
155. Kim I.B., Lee M.Y., Oh S., Kim K.Y., Chun M. Double-labeling techniques demonstrate that rod bipolar cells are under GABAergic control in the inner plexiform layer of the rat retina. Cell Tissue Res. 1998, 292(1).
156. Kim J.H., Yu Y.S., Cho C.S., Kim K.W. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J. Cereb. Blood Flow Metab. 2009, 29(3):621-628.
157. Klein R., Klein B.E., Moss S.E., Cruickshanks K.J. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105(10):1801-1815.
158. Klein R., Klein B.E., Moss S.E., Davis M.D., DeMets D.L. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 1984, 102(4):520-526.
159. Klein R., Klein B.E., Moss S.E., Davis M.D., DeMets D.L. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch. Ophthalmol. 1984, 102(4):527-532.
160. Klein R., Klein B.E., Moss S.E., Wong T.Y. Retinal vessel caliber and microvascular and macrovascular disease in type 2 diabetes: XXI: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2007, 114(10):1884-1892.
161. Klein R., Klein B.E., Moss S.E., Wong T.Y., Sharrett A.R. Retinal
162. Knowler W.C., Bennett P.H., Ballintine E.J. Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N. Engl. J. Med. 1980, 302(12):645-650.
163. Kohler K., Wheeler-Schilling T., Jurklies B., Guenther E., Zrenner E. Angiotensin II in the rabbit retina. Vis. Neurosci. 1997, 14(1):63-71.
164. Kordonouri O., Wladimirowa A., Danne T. High total serum renin concentrations are associated with the development of background retinopathy in adolescents with type 1 diabetes. Diabetes Care 2000, 23(7):1025-1026.
165. Krege J.H., Kim H.S., Moyer J.S., Jennette J.C., Peng L., Hiller S.K., Smithies O. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 1997, 29(1 Pt 2):150-157.
166. Kunisaki M., Bursell S.E., Umeda F., Nawata H., King G.L. Prevention of diabetes-induced abnormal retinal blood flow by treatment with d-alpha-tocopherol. Biofactors 1998, 7(1-2):55-67.
167. Kurihara T., Ozawa Y., Nagai N., Shinoda K., Noda K., Imamura Y., Tsubota K., Okano H., Oike Y., Ishida S. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008, 57(8):2191-2198.
168. Kurihara T., Ozawa Y., Shinoda K., Nagai N., Inoue M., Oike Y., Tsubota K., Ishida S., Okano H. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest. Ophthalmol. Vis. Sci. 2006, 47(12):5545-5552.
169. Kvakan H., Kleinewietfeld M., Qadri F., Park J.K., Fischer R., Schwarz I., Rahn H.P., Plehm R., Wellner M., Elitok S., Gratze P., Dechend R., Luft F.C., Muller D.N. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009, 119(22):2904-2912.
170. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993, 329(20):1456-1462.
171. Li J., Culman J., Hortnagl H., Zhao Y., Gerova N., Timm M., Blume A., Zimmermann M., Seidel K., Dirnagl U., Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J. 2005, 19(6):617-619.
172. Li P., Chappell M.C., Ferrario C.M., Brosnihan K.B. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997, 29(1 Pt 2):394-400.
173. Liu K., Akula J.D., Falk C., Hansen R.M., Fulton A.B. The retinal vasculature and function of the neural retina in a rat model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2006, 47(6):2639-2647.
174. Loeliger M., Briscoe T., Lambert G., Caddy J., Rehn A., Dieni S., Rees S. Chronic placental insufficiency affects retinal development in the guinea pig. Invest. Ophthalmol. Vis. Sci. 2004, 45(7):2361-2367.
175. Lonchampt M., Pennel L., Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest. Ophthalmol. Vis. Sci. 2001, 42(2):429-432.
176. Lucius R., Gallinat S., Busche S., Rosenstiel P., Unger T. Beyond blood pressure: new roles for angiotensin II. Cell. Mol. Life Sci. 1999, 56(11-12):1008-1019.
177. Luetscher J.A., Kraemer F.B., Wilson D.M., Schwartz H.C., Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med. 1985, 312(22):1412-1417.
178. Lutty G.A., Chan-Ling T., Phelps D.L., Adamis A.P., Berns K.I., Chan C.K., Cole C.H., D'Amore P.A., Das A., Deng W.T., Dobson V., Flynn J.T., Friedlander M., Fulton A., Good W.V., Grant M.B., Hansen R., Hauswirth W.W., Hardy R.J., Hinton D.R., Hughes S., McLeod D.S., Palmer E.A., Patz A., Penn J.S., Raisler B.J., Repka M.X., Saint-Geniez M., Shaw L.C., Shima D.T., Smith B.T., Smith L.E., Tahija S.G., Tasman W., Trese M.T. Proceedings of the third international symposium on retinopathy of prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol. Vis. 2006, 12:532-580.
179. Ma J.X., Song Q., Hatcher H.C., Crouch R.K., Chao L., Chao J. Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. Exp. Eye Res. 1996, 63(1):19-26.
180. Maillard M.P., Wurzner G., Nussberger J., Centeno C., Burnier M., Brunner H.R. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin. Pharmacol. Ther. 2002, 71(1):68-76.
181. Marc R.E., Murry R.F., Basinger S.F. Pattern recognition of amino acid signatures in retinal neurons. J. Neurosci. 1995, 15(7 Pt 2):5106-5129.
182. Martin P.M., Roon P., Van Ells T.K., Ganapathy V., Smith S.B. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest. Ophthalmol. Vis. Sci. 2004, 45(9):3330-3336.
183. Mauer M., Zinman B., Gardiner R., Suissa S., Sinaiko A., Strand T., Drummond K., Donnelly S., Goodyer P., Gubler M.C., Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 2009, 361(1):40-51.
184. McCall M.A., Lukasiewicz P.D., Gregg R.G., Peachey N.S. Elimination of the rho1 subunit abolishes GABA(C) receptor expression and alters visual processing in the mouse retina. J. Neurosci. 2002, 22(10):4163-4174.
185. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., Chai S.Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell. Biol. 2003, 35(6):901-918.
186. Menger N., Pow D.V., Wässle H. Glycinergic amacrine cells of the rat retina. J. Comp. Neurol. 1998, 401(1):34-46.
187. Metea M.R., Newman E.A. Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling. J. Neurosci. 2006, 26(11):2862-2870.
188. Millan M.A., Jacobowitz D.M., Aguilera G., Catt K.J. Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(24):11440-11444.
189. Mohamed S., Schaa K., Cooper M.E., Ahrens E., Alvarado A., Colaizy T., Marazita M.L., Murray J.C., Dagle J.M. Genetic contributions to the development of retinopathy of prematurity. Pediatr. Res. 2009, 65(2):193-197.
190. Mooser V., Nussberger J., Juillerat L., Burnier M., Waeber B., Bidiville J., Pauly N., Brunner H.R. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 1990, 15(2):276-282.
191. Moravski C.J., Kelly D.J., Cooper M.E., Gilbert R.E., Bertram J.F., Shahinfar S., Skinner S.L., Wilkinson-Berka J.L. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000, 36(6):1099-1104.
192. Moravski C.J., Skinner S.L., Stubbs A.J., Sarlos S., Kelly D.J., Cooper M.E., Gilbert R.E., Wilkinson-Berka J.L. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am. J. Pathol. 2003, 162(1):151-160.
193. Mori F., Hikichi T., Nagaoka T., Takahashi J., Kitaya N., Yoshida A. Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. Br. J. Ophthalmol. 2002, 86(10):1172-1174.
194. Morinelli T.A., Walker L.P., Ullian M.E. COX-2 expression stimulated by Angiotensin II depends upon AT1 receptor internalization in vascular smooth muscle cells. Biochim. Biophys. Acta 2008, 1783(6):1048-1054.
195. Muller D.N., Klanke B., Feldt S., Cordasic N., Hartner A., Schmieder R.E., Luft F.C., Hilgers K.F. (Pro)renin receptor peptide inhibitor " handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008, 51(3):676-681.
196. Mulligan S.J., MacVicar B.A. Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 2004, 431(7005):195-199.
197. Mullins J.J., Peters J., Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990, 344(6266):541-544.
198. Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., Bernstein K.E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991, 351(6323):233-236.
199. Nadal J.A., Scicli G.M., Carbini L.A., Nussbaum J.J., Scicli A.G. Angiotensin II and retinal pericytes migration. Biochem. Biophys. Res. Commun. 1999, 266(2):382-385.
200. Nadal J.A., Scicli G.M., Carbini L.A., Scicli A.G. Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB. Am. J. Physiol. Heart Circ. Physiol. 2002, 282(2):H739-H748.
201. Nagai N., Izumi-Nagai K., Oike Y., Koto T., Satofuka S., Ozawa Y., Yamashiro K., Inoue M., Tsubota K., Umezawa K., Ishida S. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest. Ophthalmol. Vis. Sci. 2007, 48(9):4342-4350.
202. Nagai N., Noda K., Urano T., Kubota Y., Shinoda H., Koto T., Shinoda K., Inoue M., Shiomi T., Ikeda E., Tsubota K., Suda T., Oike Y., Ishida S. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest. Ophthalmol. Vis. Sci. 2005, 46(3):1078-1084.
203. Nagai N., Oike Y., Izumi-Nagai K., Koto T., Satofuka S., Shinoda H., Noda K., Ozawa Y., Inoue M., Tsubota K., Ishida S. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest. Ophthalmol. Vis. Sci. 2007, 48(5):2321-2326.
204. Nagai N., Oike Y., Izumi-Nagai K., Urano T., Kubota Y., Noda K., Ozawa Y., Inoue M., Tsubota K., Suda T., Ishida S. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb. Vasc. Biol. 2006, 26(10):2252-2259.
205. Nakajima M., Hutchinson H.G., Fujinaga M., Hayashida W., Morishita R., Zhang L., Horiuchi M., Pratt R.E., Dzau V.J. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(23):10663-10667.
206. Neumann S., Huse K., Semrau R., Diegeler A., Gebhardt R., Buniatian G.H., Scholz G.H. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002, 39(3):756-760.
207. Newman E.A. Propagation of intercellular calcium waves in retinal astrocytes and Muller cells. J. Neurosci. 2001, 21(7):2215-2223.
208. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002, 109(11):1417-1427.
209. Nussberger J., de Gasparo M., Juillerat L., Guyenne T.T., Mooser V., Waeber B., Brunner H.R. Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A. Clin. Exp. Hypertens. A 1987, 9(8-9):1353-1366.
210. O'Connor A.R., Stephenson T., Johnson A., Tobin M.J., Moseley M.J., Ratib S., Ng Y., Fielder A.R. Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics 2002, 109(1):12-18.
211. Orlidge A., D'Amore P.A. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J. Cell. Biol. 1987, 105(3):1455-1462.
212. Osborne N.N., Casson R.J., Wood J.P., Chidlow G., Graham M., Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 2004, 23(1):91-147.
213. Ostroy S.E., Frede S.M., Wagner E.F., Gaitatzes C.G., Janle E.M. Decreased rhodopsin regeneration in diabetic mouse eyes. Invest. Ophthalmol. Vis. Sci. 1994, 35(11):3905-3909.
214. Otani A., Takagi H., Oh H., Koyama S., Honda Y. Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 2001, 50:867-875.
215. Otani A., Takagi H., Oh H., Suzuma K., Matsumura M., Ikeda E., Honda Y. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest. Ophthalmol. Vis. Sci. 2000, 41(5):1192-1199.
216. Otani A., Takagi H., Suzuma K., Honda Y. Angiotensin II potentiates endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 1998, 82:619-628.
217. Otani A., Takagi H., Suzuma K., Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 1998, 82(5):619-628.
218. Ottlecz A., Bensaoula T. Captopril ameliorates the decreased Na+, K(+)-ATPase activity in the retina of streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 1996, 37(8):1633-1641.
219. Palmer E.A., Flynn J.T., Hardy R.J., Phelps D.L., Phillips C.L., Schaffer D.B., Tung B. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991, 98(11):1628-1640.
220. Park S.H., Park J.W., Park S.J., Kim K.Y., Chung J.W., Chun M.H., Oh S.J. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 2003, 46(9):1260-1268.
221. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., Harrap S., Poulter N., Marre M., Cooper M., Glasziou P., Grobbee D.E., Hamet P., Heller S., Liu L.S., Mancia G., Mogensen C.E., Pan C.Y., Rodgers A., Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370(9590):829-840.
222. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol. Rev. 2006, 86(3):747-803.
223. Penn J.S., Tolman B.L., Henry M.M. Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest. Ophthalmol. Vis. Sci. 1994, 35(9):3429-3435.
224. Penn J.S., Tolman B.L., Lowery L.A. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest. Ophthalmol. Vis. Sci. 1993, 34(3):576-585.
225. Peppiatt C.M., Howarth C., Mobbs P., Attwell D. Bidirectional control of CNS capillary diameter by pericytes. Nature 2006, 443(7112):700-704.
226. Persson F., Rossing P., Reinhard H., Juhl T., Stehouwer C.D., Schalkwijk C., Danser A.H., Boomsma F., Frandsen E., Parving H.H. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32(10):1873-1879.
227. Phipps J.A., Clermont A.C., Sinha S., Chilcote T.J., Bursell S.E., Feener E.P. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension 2009, 53(2):175-181.
228. Phipps J.A., Feener E.P. The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney. Kidney Int. 2008, 73(10):1114-1119.
229. Phipps J.A., Fletcher E.L., Vingrys A.J. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest. Ophthalmol. Vis. Sci. 2004, 45(12):4592-4600.
230. Phipps J.A., Wilkinson-Berka J.L., Fletcher E.L. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest. Ophthalmol. Vis. Sci. 2007, 48(2):927-934.
231. Phipps J.A., Yee P., Fletcher E.L., Vingrys A.J. Rod photoreceptor dysfunction in diabetes: activation, deactivation, and dark adaptation. Invest. Ophthalmol. Vis. Sci. 2006, 47(7):3187-3194.
232. Pincus D.W., DiCicco-Bloom E.M., Black I.B. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 1990, 343(6258):564-567.
233. Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Zannad F., Neaton J., Roniker B., Hurley S., Burns D., Bittman R., Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI heart failure efficacy and survival study. Cardiovasc. Drugs Ther. 2001, 15(1):79-87.
234. Puri M.C., Rossant J., Alitalo K., Bernstein A., Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 1995, 14(23):5884-5891.
235. Puthussery T., Fletcher E.L. Neuronal expression of P2X3 purinoceptors in the rat retina. Neuroscience 2007, 146(1):403-414.
236. Qaum T., Xu Q., Joussen A., Clemens M., Qin W., Miyamoto K., Hassessian H., Wiegand S., Rudge J., Yancopoulos G., Adamis A. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 2001, 42(10):2408-2413.
237. Ramser J., Abidi F.E., Burckle C.A., Lenski C., Toriello H., Wen G., Lubs H.A., Engert S., Stevenson R.E., Meindl A., Schwartz C.E., Nguyen G. A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor. Hum. Mol. Genet. 2005, 14(8):1019-1027.
238. Reisner D.S., Hansen R.M., Findl O., Petersen R.A., Fulton A.B. Dark-adapted thresholds in children with histories of mild retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 1997, 38(6):1175-1183.
239. Rocha R., Martin-Berger C.L., Yang P., Scherrer R., Delyani J., McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143(12):4828-4836.
240. Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak D.A., Kekec B.K., Blomme E.A., McMahon E.G., Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 2002, 283(5):H1802-H1810.
241. Rockwood E.J., Fantes F., Davis E.B., Anderson D.R. The response of retinal vasculature to angiotensin. Invest. Ophthalmol. Vis. Sci. 1987, 28(4):676-682.
242. Rodriguez-Pallares J., Quiroz C.R., Parga J.A., Guerra M.J., Labandeira-Garcia J.L. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur. J. Neurosci. 2004, 20(6):1489-1498.
243. Roufail E., Soulis T., Boel E., Cooper M.E., Rees S. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia 1998, 41(12):1419-1425.
244. Sarlos S., Rizkalla B., Moravski C.J., Cao Z., Cooper M.E., Wilkinson-Berka J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF and angiopoietin. Am. J. Pathol. 2003, 163:879-887.
245. Sarlos S., Wilkinson-Berka J.L. The renin-angiotensin system and the developing retinal vasculature. Invest. Ophthalmol. Vis. Sci. 2005, 46(3):1069-1077.
246. Sato A., Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res. 2001, 29(1):13-21.
247. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376(6535):70-74.
248. Satofuka S., Ichihara A., Nagai N., Koto T., Shinoda H., Noda K., Ozawa Y., Inoue M., Tsubota K., Itoh H., Oike Y., Ishida S. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2007, 48(1):422-429.
249. Satofuka S., Ichihara A., Nagai N., Noda K., Ozawa Y., Fukamizu A., Tsubota K., Itoh H., Oike Y., Ishida S. (Pro)renin receptor promotes choroidal neovascularization by activating its signal transduction and tissue renin-angiotensin system. Am. J. Pathol. 2008, 173(6):1911-1918.
250. Satofuka S., Ichihara A., Nagai N., Noda K., Ozawa Y., Fukamizu A., Tsubota K., Itoh H., Oike Y., Ishida S. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009, 58(7):1625-1633.
251. Satofuka S., Ichihara A., Nagai N., Yamashiro K., Koto T., Shinoda H., Noda K., Ozawa Y., Inoue M., Tsubota K., Suzuki F., Oike Y., Ishida S. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest. Ophthalmol. Vis. Sci. 2006, 47(6):2686-2692.
252. Schaffer D.B., Palmer E.A., Plotsky D.F., Metz H.S., Flynn J.T., Tung B., Hardy R.J. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1993, 100(2):230-237.
253. Schonfelder U., Hofer A., Paul M., Funk R.H. In situ observation of living pericytes in rat retinal capillaries. Microvasc. Res. 1998, 56(1):22-29.
254. Schrier R.W., Estacio R.O., Mehler P.S., Hiatt W.R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat. Clin. Pract. Nephrol. 2007, 3(8):428-438.
255. Sealey J.E., Goldstein M., Pitarresi T., Kudlak T.T., Glorioso N., Fiamengo S.A., Laragh J.H. Prorenin secretion from human testis: no evidence for secretion of active renin or angiotensinogen. J. Clin. Endocrinol. Metab. 1988, 66(5):974-978.
256. Seki M., Tanaka T., Nawa H., Usui T., Fukuchi T., Ikeda K., Abe H., Takei N. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004, 53(9):2412-2419.
257. Senanayake P., Drazba J., Shadrach K., Milsted A., Rungger-Brandle E., Nishiyama K., Miura S., Karnik S., Sears J.E., Hollyfield J.G. Angiotensin II and its receptor subtypes in the human retina. Invest. Ophthalmol. Vis. Sci. 2007, 48(7):3301-3311.
258. Shan Z., Cuadra A.E., Sumners C., Raizada M.K. Characterization of a functional (pro)renin receptor in rat brain neurons. Exp. Physiol. 2008, 93(5):701-708.
259. Shirao Y., Kawasaki K. Electrical responses from diabetic retina. Prog. Retin. Eye Res. 1998, 17(1):59-76.
260. Simonsen S.E. ERG in Diabetes 1966, 403-412. Ghent. Basel. S. Karger (Ed.).
261. Simonsen S.E. The value of the oscillatory potential in selecting juvenile diabetics at risk of developing proliferative retinopathy. Acta Ophthalmol. (Copenh.) 1980, 58(6):865-878.
262. Sjolie A.K., Klein R., Porta M., Orchard T., Fuller J., Parving H.H., Bilous R., Chaturvedi N. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008, 372(9647):1385-1393.
263. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35(1):101-111.
264. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., Cherif Papst C., Smith B.A., Dahlof B. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119(4):530-537.
265. Southwell B.R., Seybold V.S., Woodman H.L., Jenkinson K.M., Furness J.B. Quantitation of neurokinin 1 receptor internalization and recycling in guinea-pig myenteric neurons. Neuroscience 1998, 87(4):925-931.
266. Sramek S.J., Wallow I.H., Day R.P., Ehrlich E.N. Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. Invest. Ophthalmol. Vis. Sci. 1988, 29(11):1749-1752.
267. Sramek S.J., Wallow I.H., Tewksbury D.A., Brandt C.R., Poulsen G.L. An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen. Invest. Ophthalmol. Vis. Sci. 1992, 33(5):1627-1632.
268. Stone J., Itin A., Alon T., Pe'er J., Gnessin H., Chan-Ling T., Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 1995, 15(7 Pt 1):4738-4747.
269. Stornetta R.L., Hawelu-Johnson C.L., Guyenet P.G., Lynch K.R. Astrocytes synthesize angiotensinogen in brain. Science (New York, NY) 1988, 242(4884):1444-1446.
270. Stroth U., Unger T. The renin-angiotensin system and its receptors. J. Cardiovasc. Pharmacol. 1999, 33(Suppl. 1):S21-S28. discussion S41-S43.
271. Striker G.E., Praddaude F., Alcazar O., Cousins S.W., Marin-Castano M.E. Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II. Am. J. Physiol. Cell Physiol 2008, 295:C1633-C1646.
272. Sugiyama T., Okuno T., Fukuhara M., Oku H., Ikeda T., Obayashi H., Ohta M., Fukui M., Hasegawa G., Nakamura N. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp. Eye Res. 2007, 85(3):406-412.
273. Sumners C., Myers L.M. Angiotensin II decreases cGMP levels in neuronal cultures from rat brain. Am. J. Physiol. 1991, 260(1 Pt 1):C79-C87.
274. Sun C., Wang J.J., Mackey D.A., Wong T.Y. Retinal vascular caliber: systemic, environmental, and genetic associations. Surv. Ophthalmol. 2009, 54(1):74-95.
275. Suzuki F., Hayakawa M., Nakagawa T., Nasir U.M., Ebihara A., Iwasawa A., Ishida Y., Nakamura Y., Murakami K. Human prorenin has " gate and handle" regions for its non-proteolytic activation. J. Biol. Chem. 2003, 278(25):22217-22222.
276. Suzuma I., Hata Y., Clermont A., Pokras F., Rook S.L., Suzuma K., Feener E.P., Aiello L.P. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 2001, 50(2):444-454.
277. Tadesse M., Yan Y., Yossuck P., Higgins R.D. Captopril improves retinal neovascularization via endothelin-1. Invest. Ophthalmol. Vis. Sci. 2001, 42(8):1867-1872.
278. Takahashi N., Hagaman J.R., Kim H.S., Smithies O. Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system. Endocrinology 2003, 144(6):2184-2190.
279. Takano T., Tian G.F., Peng W., Lou N., Libionka W., Han X., Nedergaard M. Astrocyte-mediated control of cerebral blood flow. Nat. Neurosci. 2006, 9(2):260-267.
280. Takeda H., Kimura Y., Higashida H., Yokoyama S. Localization of B2 bradykinin receptor mRNA in the rat retina and sclerocornea. Immunopharmacology 1999, 45(1-3):51-55.
281. Tamura K., Nyui N., Tamura N., Fujita T., Kihara M., Toya Y., Takasaki I., Takagi N., Ishii M., Oda K., Horiuchi M., Umemura S. Mechanism of angiotensin II-mediated regulation of fibronectin gene in rat vascular smooth muscle cells. J. Biol. Chem. 1998, 273(41):26487-26496.
282. Tikellis C., Johnston C.I., Forbes J.M., Burns W.C., Burrell L.M., Risvanis J., Cooper M.E. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003, 41(3):392-397.
283. Tikellis C., Johnston C.I., Forbes J.M., Burns W.C., Thomas M.C., Lew R.A., Yarski M., Smith A.I., Cooper M.E. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr. Eye Res. 2004, 29(6):419-427.
284. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993, 45(2):205-251.
285. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000, 275(43):33238-33243.
286. Tout S., Chan-Ling T., Hollander H., Stone J. The role of Muller cells in the formation of the blood-retinal barrier. Neuroscience 1993, 55:291-301.
287. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317(7160):703-713.
288. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998, 317(7160):713-720.
289. Vaajanen A., Vapaatalo H., Kautiainen H., Oksala O. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest. Ophthalmol. Vis. Sci. 2008, 49(6):2557-2562.
290. van den Heuvel M., Batenburg W.W., Danser A.H. Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis?. Mol. Cell. Endocrinol. 2009, 302(2):213-218.
291. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002, 277(17):14838-14843.
292. Vogh B.P., Godman D.R. Effects of inhibition of angiotensin converting enzyme and carbonic anhydrase on fluid production by ciliary process, choroid plexus, and pancreas. J. Ocul. Pharmacol. 1989, 5(4):303-311.
293. Wachtmeister L. Oscillatory potentials in the retina: what do they reveal. Prog. Retin. Eye Res. 1998, 17(4):485-521.
294. Wagner J., Danser A.H.J., Derkx F.H.M., de Jong P.T.V.M., Paul M., Mullins J.J., Schalekamp M.A.D.H., Ganten D. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br. J. Ophthalmol. 1996, 80:159-163.
295. Wallow I.H., Sramek S.J., Bindley C.D., Darjatmoko S.R., Gange S.J. Ocular renin angiotensin: EM immunocytochemical localization of prorenin. Curr. Eye Res. 1993, 12(10):945-950.
296. Wang D., Martens J.R., Posner P., Sumners C., Gelband C.H. Angiotensin II regulation of intracellular calcium in astroglia cultured from rat hypothalamus and brainstem. J. Neurochem. 1996, 67(3):996-1004.
297. Wang G., Anrather J., Glass M.J., Tarsitano M.J., Zhou P., Frys K.A., Pickel V.M., Iadecola C. Nox2, Ca2+, and protein kinase C play a role in angiotensin II-induced free radical production in nucleus tractus solitarius. Hypertension 2006, 48(3):482-489.
298. Wässle H. Parallel processing in the mammalian retina. Nat. Rev. Neurosci. 2004, 5(10):747-757.
299. Wässle H., Grunert U., Rohrenbeck J. Immunocytochemical staining of AII-amacrine cells in the rat retina with antibodies against parvalbumin. J. Comp. Neurol. 1993, 332(4):407-420.
300. Watanabe T., Raff M.C. Retinal astrocytes are immigrants from the optic nerve. Nature 1988, 332(6167):834-837.
301. Wax M.B., Tezel G., Edward P.D. Clinical and ocular histopathological findings in a patient with normal-pressure glaucoma. Arch. Ophthalmol. 1998, 116(8):993-1001.
302. Wetzel R.K., Arystarkhova E., Sweadner K.J. Cellular and subcellular specification of Na, K-ATPase alpha and beta isoforms in the postnatal development of mouse retina. J. Neurosci. 1999, 19(22):9878-9889.
303. Weymouth A.E., Vingrys A.J. Rodent electroretinography: methods for extraction and interpretation of rod and cone responses. Prog. Retin. Eye Res. 2008, 27(1):1-44.
304. Whaley-Connell A., Govindarajan G., Habibi J., Hayden M.R., Cooper S.A., Wei Y., Ma L., Qazi M., Link D., Karuparthi P.R., Stump C., Ferrario C., Sowers J.R. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am. J. Physiol. Endocrinol. Metab. 2007, 293(1):E355-E363.
305. Whaley-Connell A.T., Nistala R., Habibi J., Hayden M.R., Schneider R.I., Johnson M.S., Tilmon R., Rehmer N., Ferrario C.M., Sowers J.R. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 Rat. Am. J. Physiol. Renal. Physiol. 2009.
306. Wheeler-Schilling T.H., Kohler K., Sautter M., Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur. J. Neurosci. 1999, 11(10):3387-3394.
307. Wheeler-Schilling T.H., Sautter M., Guenther E., Kohler K. Expression of angiotensin-converting enzyme (ACE) in the developing chicken retina. Exp. Eye Res. 2001, 72(2):173-182.
308. Wilkinson-Berka J.L., Campbell D.J. (Pro)renin receptor: a treatment target for diabetic retinopathy?. Diabetes 2009, 58(7):1485-1487.
309. Wilkinson-Berka J.L., Fletcher E.L. Angiotensin and bradykinin: targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy. Curr. Pharm. Des. 2004, 10(27):3313-3330.
310. Wilkinson-Berka J.L., Tan G., Jaworski K., Miller A.G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 2009, 104(1):124-133.
311. Wilkinson-Berka J.L., Tan G., Jaworski K., Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am. J. Hypertens. 2007, 20(4):423-430.
312. Wilson A.S., Hobbs B.G., Shen W.Y., Speed T.P., Schmidt U., Begley C.G., Rakoczy P.E. Argon laser photocoagulation-induced modification of gene expression in the retina. Invest. Ophthalmol. Vis. Sci. 2003, 44(4):1426-1434.
313. Wilson D.M., Luetscher J.A. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N. Engl. J. Med. 1990, 323(16):1101-1106.
314. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003, 22(1):1-29.
315. Wosik K., Cayrol R., Dodelet-Devillers A., Berthelet F., Bernard M., Moumdjian R., Bouthillier A., Reudelhuber T.L., Prat A. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 2007, 27(34):9032-9042.
316. Wright J.W., Harding J.W. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Rev. 1997, 25(1):96-124.
317. Yanai K., Saito T., Kakinuma Y., Kon Y., Hirota K., Taniguchi-Yanai K., Nishijo N., Shigematsu Y., Horiguchi H., Kasuya Y., Sugiyama F., Yagami K., Murakami K., Fukamizu A. Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J. Biol. Chem. 2000, 275(1):5-8.
318. Yang H., Hirooka K., Fukuda K., Shiraga F. Neuroprotective effects of angiotensin II Type 1 receptor blocker in a rat model of chronic glaucoma. Invest. Ophthalmol. Vis. Sci. 2009.
319. Ye M., Wysocki J., William J., Soler M.J., Cokic I., Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 2006, 17(11):3067-3075.
320. Yokota H., Nagaoka T., Mori F., Hikichi T., Hosokawa H., Tanaka H., Ishida Y., Suzuki F., Yoshida A. Prorenin levels in retinopathy of prematurity. Am. J. Ophthalmol. 2007, 143(3):531-533.
321. Zhang G.X., Lu X.M., Kimura S., Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc. Res. 2007, 76(2):204-212.
322. Zhang S.X., Wang J.J., Gao G., Parke K., Ma J.X. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J. Mol. Endocrinol. 2006, 37(1):1-12.
323. Zhang X., Lassila M., Cooper M.E., Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004, 43(2):276-281.
324. Zhang Y., Stone J. Role of astrocytes in the control of developing retinal vessels. Invest. Ophthalmol. Vis. Sci. 1997, 38(9):1653-1666.
325. Zheng Z., Chen H., Ke G., Fan Y., Zou H., Sun X., Gu Q., Xu X., Ho P.C. Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway. Diabetes 2009, 58(4):954-964.
326. Zheng Z., Chen H., Xu X., Li C., Gu Q. Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp. Eye Res. 2007, 84(4):745-752.